ACTRN12606000310561尚未招募不适用
DORADO-EX – A Dose-Blinded, Long-Term Safety Extension Study of Fixed Doses of Darusentan in Subjects with Resistant Systolic Hypertension Receiving Combination Therapy with Four of More Antihypertensive Drugs, Including a Diuretic (Protocol DAR-311-E)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- Myogen, Inc.
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- ot stated 至 ot stated（—）
- 性别
- All
入选标准
- •1) Subjects who have completed the Treatment Period of clinical trial DAR-311; 2) Receiving and adhering to full doses of appropriate guideline-recommended antihypertensive drugs from four different classes of antihypertensive agents, including a diuretic.
排除标准
- •1) Subjects who discontinued treatment with study drug prior to the end of the Treatment Period of DAR-311 due to a study drug-related AE; 2) Subjects who experience a study drug-related SAE during the DAR-311 study.
研究者
相似试验
进行中（未招募）
1 期
DORADO-EX – A Dose-Blinded, Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant HypertensionA Dose-Blinded, Long-Term Safety Extension Study of Fixed Doses of Darusentan in Subjects with Resistant Systolic Hypertension Receiving Combination Therapy with Three or More Antihypertensive Drugs, Including a DiureticDORADO-EX - Estudio de extensión de la seguridad a largo plazo, con enmascaramiento de la dosis, del estudio DORADO en fase 3 (protocolo DAR 311) de darusentán en la hipertensión arterial resistente Estudio de extensión de la seguridad a largo plazo, con enmascaramiento de la dosis, de dosis fijas de darusentán en sujetos con hipertensión sistólica resistente tratados con una combinación de tres o más antihipertensivos, incluido un diurético (protocolo DAR-311-E) - DORADO-EXEUCTR2006-001899-20-ESGilead Sciences Inc.300
进行中（未招募）
1 期
DORADO-EX – A Dose-Blinded, Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant HypertensionA Dose-Blinded, Long-Term Safety Extension Study of Fixed Doses of Darusentan in Subjects with Resistant Systolic Hypertension Receiving Combination Therapy with Three or More Antihypertensive Drugs, Including a Diuretic - DORADO-EXMedDRA version: 8.1Level: LLTClassification code 10038274Term: Refractory hypertensionResistant hypertensionEUCTR2006-001899-20-FRGilead Sciences Inc.300
进行中（未招募）
不适用
DORADO-EX – A Dose-Blinded, Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant HypertensionA Dose-Blinded, Long-Term Safety Extension Study of Fixed Doses of Darusentan in Subjects with Resistant Systolic Hypertension Receiving Combination Therapy with Three or More Antihypertensive Drugs, Including a Diuretic - DORADO-EXResistant hypertensionEUCTR2006-001899-20-DEGilead Sciences Inc.377
进行中（未招募）
不适用
DORADO-EX – A Dose-Blinded, Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant HypertensionA Dose-Blinded, Long-Term Safety Extension Study of Fixed Doses of Darusentan in Subjects with Resistant Systolic Hypertension Receiving Combination Therapy with Three or More Antihypertensive Drugs, Including a Diuretic - DORADO-EXMedDRA version: 8.1Level: LLTClassification code 10038274Term: Refractory hypertensionResistant hypertensionEUCTR2006-001899-20-SEGilead Sciences Inc.377
进行中（未招募）
1 期
DORADO-EX – A Dose-Blinded, Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant HypertensionA Dose-Blinded, Long-Term Safety Extension Study of Fixed Doses of Darusentan in Subjects with Resistant Systolic Hypertension Receiving Combination Therapy with Three or More Antihypertensive Drugs, Including a Diuretic - DORADO-EXResistant hypertensionEUCTR2006-001899-20-GBGilead Sciences Inc.377